

## ELEVATED PLASMA CYCLOPHILIN A IN HEMODIALYSIS AND PERITONEAL DIALYSIS PATIENTS: A NOVEL LINK TO SYSTEMIC **INFLAMMATION AND CARDIOVASCULAR DISEASE**

Kyubok Jin<sup>1</sup>, Nosratola D. Vaziri<sup>2</sup>, Yaerim Kim<sup>1</sup>, Seong Sik Kang<sup>1</sup>, Woo Yeong Park<sup>1</sup>, Seungyeup Han<sup>1</sup>, Sung Bae Park<sup>1</sup>, Sihyung Park<sup>3</sup>, Jeongsoo Yoon<sup>4</sup>

<sup>1</sup>Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea <sup>2</sup>Division of Nephrology and Hypertension, University of California, Irvine, Irvine, California <sup>3</sup>Department of Medicine, Inje University, Haeundae Paik Hospital, Busan, Korea <sup>4</sup>Yoon's internal medicine clinic



Table 1. General data on hemodialysis, peritoneal dialysis, and healthy control groups

Cyclophilin A (CyPA) has emerged as a novel mediator of oxidative stress and inflammation and a major player in cardiovascular disease, diabetes, viral infections, and neurodegenerative and thrombotic disorders. CyPA is an abundant intra-cellular protein which is released by certain cell types spontaneously or in response to inflammatory mediators, hypoxia, oxidative stress and hyperglycemia. Many of these conditions are either present or frequently occur in ESRD patients and can thus stimulate release of CyPA thereby amplifying systemic inflammation. To our knowledge, the effect of ESRD and dialysis modalities on circulating CyPA has not been previously investigated. This study tested the hypothesis that extracellular CyPA is elevated in ESRD patients maintained on hemodialysis and peritoneal dialysis.



CyPA, hsCRP, and lipid levels were measured in the fasting plasma samples from 20 hemodialysis and 20 peritoneal dialysis patients, and 20 healthy ageand gender-matched controls. Left ventricular (LV) mass, LV end-systolic and end-diastolic volumes, ejection fraction and and pulse wave velocity and anklebrachial index were determined.

	Control	Hemodialysis	Peritoneal dialysis
Age (y)	47.7 ± 8.5	49.4 ± 11.8	50.1 ± 8.4
Female sex (%)	10 (50)	10 (50)	10 (50)
Systolic blood pressure (mmHg)	118.9 ± 7.2	140.7 ± 17.8 <sup>a</sup>	138.5 ± 26.4ª
Diastolic blood pressure (mmHg)	76.8 ± 8.1	85.5 ± 15.1ª	84.0 ± 13.1ª
Body mass index (kg/m <sup>2</sup> )	23.3 ± 3.4	24.2 ± 3.8	25.1 ± 3.1
Hemoglobin (g/dl)	14.2 ± 1.6	$10.1 \pm 0.8^{a}$	10.2 ± 1.1
Serum albumin (g/dl)	4.5 ± 0.2	3.6 ± 0.3 <sup>a</sup>	$3.2 \pm 0.5^{a,d}$
Calcium (mmol/l)	9.5 ±0.4	8.3 ± 0.5 <sup>b</sup>	8.2 ± 0.7 <sup>a</sup>
Phosphorus (mmol/l)	3,5 ± 0.8	5.9 ± 2.2 <sup>a</sup>	5.4 ± 1.9 <sup>a</sup>
$Ca X P (mg^2/dl^2)$	33.2 ± 8.6	48.5 ± 17.3ª	44.2 ± 15.3 <sup>a</sup>
Serum urea nitrogen (mg/dl)	11.5 ± 2.8	76.9 ± 29.0 <sup>a</sup>	57.2 ± 16.2ª
Serum creatinine (mg/dl)	0.9 ± 0.2	10.6 ± 2.6 <sup>a</sup>	$10.6 \pm 4.6^{a}$
hs-CRP (mg/dl)	0.03 ± 0.01	0.29 ± 0.29 <sup>a</sup>	$0.24 \pm 0.24^{a}$
Total cholesterol (mg/dl)	178.4 ± 34.1	153.1 ± 31.3 <sup>ь</sup>	212.3 ± 30.8 <sup>a,d</sup>
LDL cholesterol (mg/dl)	85.1 ± 27.4	88.3 ± 24.5 <sup>b</sup>	135.8 ± 19.9 <sup>a,d</sup>
HDL cholesterol (mg/dl)	54.3 ± 111.1	40.1 ± 9.9 <sup>b</sup>	36.6 ± 8.9 <sup>a</sup>
Triglyceride (mg/dl)	93.5 ± 45.6	113.5 ± 64.5	194.0 ± 97.6 <sup>a,c</sup>
Atherogenic index of plasma	0.19 ± 0.06	$0.43 \pm 0.08^{a}$	$0.64 \pm 0.07^{a,d}$
Body mass index (kg/m <sup>2</sup> )	22.3 ± 3.4	24.2 ± 3.8	25.1 ± 3.1
CK-MB (ng/ml)	1.7 <b>±</b> 0.4	2.4 ± 1.7	2.9 ± 2.4
cTnI (ng/ml)	$0.02 \pm 0.01$	0.03 ± 0.03	0.05 ± 0.09
Uric acid (mg/dl)	4.2 ± 1.2	7.4 ± 1.5 <sup>a</sup>	7.3 ± 1.5 <sup>a</sup>
Cyclophillin A (ng/ml)	57.5 ± 17.8	104.5 ± 19.5 <sup>a</sup>	106.2 ± 35.2 <sup>a</sup>


RESULTS

Plasma CyPA concentration in the hemodialysis (105.3 ± 6.2 ng/ml) and PD (106.8 ± 9.0 ng/ml) groups were significantly higher than that in the control group (29.7 ± 4.1 ng/ml). This was associated with significant elevation of hsCRP, IL-6, TNF- $\alpha$ , plasma atherogenic index [log(triglyceride/HDLcholesterol)], systolic and diastolic blood pressure, LV mass, LV end-diastolic and end-systolic volumes, and pulse wave velocity coupled with significant reduction in LV ejection fraction and ankle-brachial index. Plasma CyPA concentration showed direct correlation with hsCRP, IL-6, TNF- $\alpha$ , plasma atherogenic index, pulse wave velocity, systolic and diastolic blood pressure and inverse correlation with ankle-brachial index and HDL-cholesterol concentration.

Table 2. Plasma cyclophilin A, hs-CRP, IL-6, and TNF-α concentrations in hemodilaysis, peritoneal dialysis and healthy control group

	Control (n=20)	Hemodialysis (n=20)	Peritoneal dialysis (n=20)
Cyclophillin A (ng/ml)	29.7 ± 4.1	105.3 ± 6.2ª	106.8 ± 9.0ª
hs-CRP (mg/dl)	$0.03~\pm~0.01$	0.29 ± 0.29ª	$0.24 \pm 0.24^{a}$
IL-6 (pg/ml)	1.3 ± 0.2	$5.2 \pm 0.4^{a}$	$5.2 \pm 0.5^{a}$
TNF-α (pg/ml)	$1.4 \pm 0.1$	$4.6 \pm 0.2^{a}$	4.8 ± 0.3ª

*Fig. 1.* Box plots depicting plasma cyclophilin A concentrations in the control, hemodialysis and peritoneal dialysis group



a = P < 0.01 versus control group; b = P < 0.05 versus control group; c = P < 0.01 versus hemodialysis group; d = P < 0.05 versus hemodialysis group.



Plasma CyPA concentration is markedly elevated and positively correlates with the markers of systemic inflammation and cardiovascular disease in hemodialysis and peritoneal dialysis patients.



Keimyung University **Dongsan Medical Center** 



Kyubok Jin

Dialysis. Protein-energy wasting, inflammation and oxidative stress.

DOI: 10.3252/pso.eu.53era.2016

ePosters supported by F. Hoffmann- I Roche Ltd



